Selective Activation Of Retinal Networks In Response To High Frequency Electrical Stimulation: A Computational Modelling, In Vitro And In Vivo Study
Funder
National Health and Medical Research Council
Funding Amount
$955,197.00
Summary
Arguably the greatest challenge facing designing a more effective bionic eye occurs at the interface between the electrodes and the retina. We will investigate new ways of steering electricity that will allow stimulation to specifically target pre-determined areas and cells in the retina. While contributing directly to our knowledge of how the retina functions, the work will also be a critical enabler of improved vision processing and stimulation strategies in future generations of a bionic eye.
What Is The Effect Of Alzheimer’s Disease On Eye And Can Ocular Changes Be Used As Biomarker For Alzheimer’s Disease?
Funder
National Health and Medical Research Council
Funding Amount
$718,002.00
Summary
Visual symptoms are frequent early complaints in Alzheimer’s (AD) patients. Examining eyes can be a simple, specific and inexpensive way to assess and diagnose AD and fill in an urgent need for a viable biomarker. Retina is unique part of central nervous system that can be imaged non-invasively and thus serves as a ‘window to the brain”. Monitoring the eyes will also help prevent negative effects of AD on vision by way of timely intervention, in addition to providing mechanistic insights in AD.
Energy Supply In Glaucoma: One Cell's Trash Is Another Cell's Treasure
Funder
National Health and Medical Research Council
Funding Amount
$122,712.00
Summary
Glaucoma is a leading cause of blindness and affects 65 million people worldwide, yet its underlying cause is not well understood. The work described in this research aims to understand the role of oligodendrocytes in provision of energy to retinal ganglion cell axons, and whether impaired energy supply in retinal ganglion cell axons and the optic nerve will lead to glaucoma. It is expected to provide new insight into glaucoma and potentially lead to new treatments.
Glaucoma is a leading cause of irreversible blindness, and its management is hindered by the lack of effective clinical measures of the disease. This project seeks to develop new clinical tests to take the “guesswork” out of its management – measures that can correctly identify those at high-risk of progression, accurately determine treatment efficacy and sensitively detect disease progression, thus preventing the irreversible loss of vision from this disease.